US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

59.97

-0.2382-0.40%

Volume:14.50K

Turnover:875.25K

Market Cap:290.25M

PE:19.62

High:60.40

Open:60.28

Low:59.85

Close:60.21

52wk High:64.10

52wk Low:44.47

Shares:4.84M

Float Shares:4.84M

Volume Ratio:1.26

T/O Rate:0.30%

Dividend:1.52

Dividend Rate:2.54%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says

MT Newswires Live

UL Solutions warns of unauthorizd UL marks on carbon monoxide detectors

Revolution Medicines Director Elizabeth M. Anderson Disposes of $1,949,321.86 in Common Shares

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Huihe Medical's STAR Market IPO Application Terminated; Company Focuses on Innovative Medical Devices in Panvascular Intervention

Lifetech Scientific's SureCham Aortic Arch Single-Branch Stent Graft System Enters Special Review Pathway for Innovative Medical Devices

Bioperfectus Secures Two Medical Device Registration Certificates

Maccura Biotechnology Secures Three Medical Device Registration Certificates

Revolution Medicines (RVMD) Gets a Buy from Goldman Sachs

Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback

Sector Update: Healthcare

MT Newswires Live

Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks

MT Newswires Live

Roivant Sciences price target raised to $41 from $37.50 at BofA

Immunovant Falls After Lupus Drug Setback

Roivant Says IMVT-1402 Cutaneous Lupus Study Misses Primary Endpoint, Halts Development in CLE

Roivant Sciences - Imvt-1402 Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS

Roivant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus

THOMSON REUTERS

Roivant Sciences - All Other Clinical Development Timelines Remain on Track

THOMSON REUTERS

Axsome Therapeutics, Inc. : Truist Securities Assumes Coverage with Buy Rating; Target Price $285 vs $200

THOMSON REUTERS

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/PTH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":59.97,"timestamp":1791212047220,"preClose":60.2082,"halted":0,"volume":14503,"delay":0,"changeRate":-0.003956271737072344,"floatShares":4840000,"shares":4840000,"eps":3.057033,"marketStatus":"Trading","change":-0.2382,"latestTime":"10-05 10:59:23 EDT","open":60.28,"high":60.4,"low":59.85,"amount":875250.82892,"amplitude":0.009135,"askPrice":60.21,"askSize":1000,"bidPrice":60.06,"bidSize":1300,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791230400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":60.2082,"sharesOutstanding":2480000,"nav":59.60729,"aum":291451253.04,"dividendRate":0.025401,"bidAskSpread":0.001966,"preHourTrading":{"tag":"盘前","latestPrice":60.2082,"preClose":60.2082,"latestTime":"07:36 EDT","volume":16,"amount":963.658208,"timestamp":1791200176330,"change":0,"changeRate":0,"amplitude":0.000362},"postHourTrading":{"tag":"盘后","latestPrice":60.2,"preClose":60.2082,"latestTime":"19:30 EDT","volume":10,"amount":602.441,"timestamp":1790983804674,"change":-0.0082,"changeRate":-0.000136,"amplitude":0},"volumeRatio":1.257374,"impliedVol":0.1253,"impliedVolPercentile":0.5498},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.257374,"shares":4840000,"dividePrice":1.5233,"high":60.4,"amplitude":0.009135,"preClose":60.2082,"low":59.85,"week52Low":44.47,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":59.97,"committee":0.130435,"eps":3.057033,"divideRate":0.025401,"volume":14503,"delay":0,"ttmEps":3.057033,"open":60.28,"prevYearClose":49.701,"prevWeekClose":60.2082,"prevMonthClose":60.76,"prevQuarterClose":60.76,"fiveDayClose":61.8701,"twentyDayClose":61.1284,"sixtyDayClose":59.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670607429","title":"Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670607429","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670607429?lang=en_us&edition=fundamental","pubTime":"2026-09-26 01:42","pubTimestamp":1790358164,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics  may benefit from continued momentum for its depression and Alzheimer's agitation treatment Auvelity, with prescription data showing solid weekly growth, Mizuho said Friday in a report.Data from Bloomberg Symphony and IQVIA indicated double-digit percentage increases in total and new prescriptions, suggesting Auvelity's launch in Alzheimer's agitation is off to an encouraging start, the report said.The positive trends emerge as competitor Acadia Pharmaceuticals  reported weaker phase 2 results in Alzheimer's-related psychosis, which may help Axsome's positioning in the Alzheimer's and depression treatment markets, Mizuho said.Mizuho maintained its outperform rating on Axsome with a $316 price target.Price: 196.49, Change: +0.46, Percent Change: +0.23","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","LU2324357040.USD","PTH","LU2065171402.SGD","AXSM","ACAD","LU2065170008.USD","BK4139","LU2065171311.SGD","LU2065169927.USD","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670544053","title":"UL Solutions warns of unauthorizd UL marks on carbon monoxide detectors","url":"https://stock-news.laohu8.com/highlight/detail?id=2670544053","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670544053?lang=en_us&edition=fundamental","pubTime":"2026-09-25 20:36","pubTimestamp":1790339810,"startTime":"0","endTime":"0","summary":"UL Solutions (ULS) issued a public notice regarding Protech International carbon monoxide detectors, product model PTH-24D, which bear unauthorized...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ul-solutions-warns-of-unauthorizd-ul-marks-on-carbon-monoxide-detectors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ul-solutions-warns-of-unauthorizd-ul-marks-on-carbon-monoxide-detectors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4509","BK4123","LU2087625088.SGD","BK4023","LU0012050646.USD","ULS","LU0353189763.USD","BK4526","PTH","BK4505","LU0106261612.USD","TUYA","LU0353189680.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670415347","title":"Revolution Medicines Director Elizabeth M. Anderson Disposes of $1,949,321.86 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2670415347","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670415347?lang=en_us&edition=fundamental","pubTime":"2026-09-25 06:00","pubTimestamp":1790287241,"startTime":"0","endTime":"0","summary":"Revolution Medicines director Elizabeth M. Anderson disposes of $1,949,321.86 in common sharesElizabeth M. Anderson, director, cut her direct stake in Revolution Medicines common stock to 4,333 shares","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL3Nb1nM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director Elizabeth M. Anderson Disposes of $1,949,321.86 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","BK4139","PTH","LU0889565916.HKD","RVMD","LU0109394709.USD","IE0009354923.USD","BBH","CANC","IE0002141913.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499070","title":"FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499070","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499070?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:52","pubTimestamp":1790261520,"startTime":"0","endTime":"0","summary":"Mizuho's Bradley Bowers thinks the boost will be substantial. He wrote Tuesday that sales doubled in the launch years of other cancer-screening products-like colon cancer stool test Cologuard from the Exact Sciences unit of Abbott, or the colon cancer blood test Shield from Guardant Health.Galleri screens a person's blood sample for bits of DNA showing features typical of cancer cells. It tells you if it has found a general signal of cancer somewhere in your body-\"Cancer Signal Detected\"-and makes its best guess at the kind of tissue where the cancer is hiding.Clinical trials showed Galleri can detect cancers for which there is no standard screen, such as cancer of the ovary or pancreas. Grail's two big clinical trials showed that it rarely tells you that you have cancer when you don't. When you do have cancer, the test finds it on average about 50% of the 60% of the time.That is good performance, compared with other widely used screens, like the mammogram. Grail plans to tell customer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GNOM","LU0122379950.USD","LU0882574055.USD","LU2112291526.USD","LABU","BK4196","LU0289739699.SGD","TMED","LU2237957811.SGD","LU2468319806.SGD","GNMX","LU0211331839.USD","LU2089984988.USD","LU0320765489.SGD","LU0868494617.USD","GH","HELX","LU1691799644.USD","LU1989763690.USD","FFOX","IE00B2B36J28.USD","LU1721429741.USD","BK4585","IE0002141913.USD","LU1061106388.HKD","PTH","BK4139","GRAL","IE00B4R5TH58.HKD","LU0320765992.SGD","LU1670627923.USD","LU2324357040.USD","LFSC","SG9999002224.SGD","ABT","BK4535","LU0889565916.HKD","BK4551","BK4588","IHI","BK4568","SGXZ41872573.SGD","EKG","SG9999004303.SGD","BK4581","SGXZ23171101.USD","SG9999002232.USD","LU1721429402.USD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193610255","title":"Huihe Medical's STAR Market IPO Application Terminated; Company Focuses on Innovative Medical Devices in Panvascular Intervention","url":"https://stock-news.laohu8.com/highlight/detail?id=1193610255","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193610255?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:54","pubTimestamp":1790254489,"startTime":"0","endTime":"0","summary":"Huihe Medical's STAR Market IPO review status was changed to \"terminated\" on September 24, as the company and its sponsor withdrew the listing application, according to the relevant provisions of the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","REDS","LNGR","159891","MDEV","159883","09996","FRHC","BK1574","BK1100","BK1583","MEDX","AGNG","PTH","LGHT","BK4127","RSPH","IEIH","KCE","GDOC","KSTR","HART"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104658454","title":"Lifetech Scientific's SureCham Aortic Arch Single-Branch Stent Graft System Enters Special Review Pathway for Innovative Medical Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1104658454","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104658454?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:16","pubTimestamp":1790252179,"startTime":"0","endTime":"0","summary":"Lifetech Scientific (01302) has announced that on September 24, 2026, the company received formal written notification from the National Medical Products Administration confirming that the SureCham...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01302","LNGR","BK1100","LGHT","BK1583","HART","BK1600","09996","RSPH","BK1574","PTH","GDOC","MEDX","MDEV","159883","IEIH","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131609096","title":"Bioperfectus Secures Two Medical Device Registration Certificates","url":"https://stock-news.laohu8.com/highlight/detail?id=1131609096","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131609096?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:20","pubTimestamp":1790241617,"startTime":"0","endTime":"0","summary":"Bioperfectus Technologies (688399.SH) announced that it has recently received medical device registration certificates (in vitro diagnostic reagents) issued by the National Medical Products...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGNG","688399","BK1574","PTH","BK1100","159883","LGHT","MDEV","BK1583","09996","RSPH","BK0239","LNGR","GDOC","MEDX","IEIH","HART"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198667592","title":"Maccura Biotechnology Secures Three Medical Device Registration Certificates","url":"https://stock-news.laohu8.com/highlight/detail?id=1198667592","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198667592?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:59","pubTimestamp":1790240378,"startTime":"0","endTime":"0","summary":"Maccura Biotechnology Co.,Ltd. (300463.SZ) has announced that the company recently received three Medical Device Registration Certificates issued by the Sichuan Provincial Medical Products...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","HART","BK1100","PTH","BK1574","159883","BK0046","09996","MDEV","BK0028","BK0012","GDOC","LGHT","BK1583","300463","AGNG","RSPH","BK0239","MEDX","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669918463","title":"Revolution Medicines (RVMD) Gets a Buy from Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669918463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669918463?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:35","pubTimestamp":1790238933,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Andrea Newkirk resumed coverage with a Buy rating on Revolution Medicines today and set a price target of $267.00. Newkirk co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-gets-a-buy-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-gets-a-buy-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3B42.SGD","IDNA","IE00BFTCPJ56.SGD","LU0251131958.USD","LU1668664300.SGD","PTH","IE0034235188.USD","BBH","BK4550","LU0868494708.USD","LU1894683348.USD","LU2750360997.AUD","BK4127","CANC","LU2237443622.USD","IE00BFXG1179.USD","IE0009354923.USD","LU0210536198.USD","LU2471134523.USD","LU1868836591.USD","IE00BJT1NW94.SGD","LU1144417596.USD","LU2237443895.HKD","LU2237438978.USD","IE00B2B36J28.USD","LU1868836757.USD","LU0742534661.SGD","LU2896262040.SGD","LU0251142724.SGD","GSX","IE00BSNM7G36.USD","LU0345770993.USD","LU2237443978.SGD","LU2237443382.USD","LU1804176565.USD","BK4552","BK4533","BK4588","LU0106831901.USD","RVMD","LU0345770308.USD","IE0004086264.USD","IE0002270589.USD","LU0096364046.USD","LU1791807156.HKD","IE00BJJMRZ35.SGD","LU1894683264.USD","LU0942090050.USD","LU0061475181.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438437","title":"Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669438437?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:20","pubTimestamp":1790184011,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week 12 Cutaneous Lupus Er...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wainwright-maintains-confidence-in-immunovants-pipeline-despite-cle-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wainwright-maintains-confidence-in-immunovants-pipeline-despite-cle-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV","BK4007","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486413","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486413?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168425,"startTime":"0","endTime":"0","summary":"Healthcare stocks were steady premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  slightly declining and the iShares Biotechnology ETF  inactive.Roivant Sciences  said its Immunovant  subsidiary plans to stop development of IMVT-1402 in cutaneous lupus erythematosus after a proof-of-concept study failed to achieve statistical significance on the primary endpoint. Shares of Immunovant and Roivant were down 6.1% and 1%, respectively, pre-bell.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XBI","LU0128526141.USD","BK4588","BK4139","XLV","IBB","BK4007","LABU","LU0029874061.USD","ROIV","BK4581","HCSG","IMVT","BK4585","BK4137","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669372486","title":"Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2669372486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669372486?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:48","pubTimestamp":1790167737,"startTime":"0","endTime":"0","summary":"(Updates with economic data, recent oil price movements, world markets' overview, and corporate stock movements.)US equity futures were slightly lower pre-bell Wednesday as traders awaited development","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4168","ROIV","BK4585","IONX","IOYY","BK4566","BK4602","LU1670628061.USD","BK4139","IONQ","LU1670627923.USD","BK4007","CQTM","LU0300736492.USD","BK4591","CARX","IONC","WNDR","LU0300736062.USD","BK4170","LU0266013472.USD","BK4142","BK4113","BK4141","RCL","BHP","IMVT","COAL","IONL","BK4588","QTUP","BK4517","SLX","CART","WQTM","IONZ","PTH","LU1366192091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669048537","title":"Roivant Sciences price target raised to $41 from $37.50 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669048537","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669048537?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:15","pubTimestamp":1790165711,"startTime":"0","endTime":"0","summary":"BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $37.50 and keeps a Neutral rating on the shares after h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-41-from-37-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-41-from-37-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PTH","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483473","title":"Immunovant Falls After Lupus Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483473","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483473?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:04","pubTimestamp":1790165052,"startTime":"0","endTime":"0","summary":"BUZZ-Immunovant falls after lupus drug setback** Shares of biotech firm ImmunovantIMVT.Ofall 4.5% to $35.6 premarket** Stock set to open at its lowest level in over three months, if losses hold** Co p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F0L8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4585","BK4588","IMVT","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669269100","title":"Roivant Says IMVT-1402 Cutaneous Lupus Study Misses Primary Endpoint, Halts Development in CLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2669269100","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669269100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:05","pubTimestamp":1790161507,"startTime":"0","endTime":"0","summary":"Roivant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts development in CLERoivant reported topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL5xYLBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","BK4139","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","IE00BQXX3D17.EUR","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","SG9999014039.USD","BCDF","PTH","LU0314104364.USD","ROIV","BK4007","IE00BQXX3C00.GBP","IE00BKPKM429.USD","SG9999014021.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669676100","title":"Roivant Sciences - Imvt-1402 Demonstrates Favorable Safety and Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669676100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669676100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PTH","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100988","title":"Roivant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100988?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4007","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669006461","title":"Roivant Sciences - All Other Clinical Development Timelines Remain on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2669006461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669006461?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ROIV","PTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669310159","title":"Axsome Therapeutics, Inc. : Truist Securities Assumes Coverage with Buy Rating; Target Price $285 vs $200","url":"https://stock-news.laohu8.com/highlight/detail?id=2669310159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669310159?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:03","pubTimestamp":1790154221,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","AXSM","BK4585","LU2324357040.USD","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669120310","title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2669120310","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669120310?lang=en_us&edition=fundamental","pubTime":"2026-09-23 06:00","pubTimestamp":1790114446,"startTime":"0","endTime":"0","summary":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares worth $347,000Revolution Medicines Chief Global Commercialization Officer Anthony Mancini sold 1,7","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL64Mcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","LU0889565916.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","BBH","BK4139","IE0009355771.USD","RVMD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","PTH","IE0009354923.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","CANC","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}